| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2013: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
|
|---|
| Outline of Final Research Achievements |
Influenza RNA polymerase plays vital roles in the virus life cycle and, since it is much more highly conserved than other influenza virus proteins, it is of great interest as a drug target. This laboratory has created monoclonal antibodies that bind to fragments of the polymerase and block viral replication. Antibody PA11.9 binds to the PA subunit carrying the RNA polymerisation active site.
Two other antibodies were shown to bind to the RNA-binding PB2 subunit of the polymerase, including antibody PB2 3-1.6, which has notably high affinity for its target. This antibody has been patented as a research tool and diagnostic reagent (patent number 2014-068824).
|
